Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1982 Aug;35(8):800–806. doi: 10.1136/jcp.35.8.800

Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.

G A Turner, R D Ellis, D Guthrie, A L Latner, J M Monaghan, W M Ross, A W Skillen, R G Wilson
PMCID: PMC497792  PMID: 6286732

Abstract

Cyclic guanosine 3',5' monophosphate (cyclic GMP) and cyclic adenosine 3',5' monophosphate (cyclic AMP) have been determined in random urine specimens from 95 healthy individuals, 60 patients with non-cancerous conditions, 52 patients with benign tumours, and 74 patients with malignant tumours. Concentrations of cyclic GMP have also been determined in a number of other groups, including some undergoing cancer treatment. Ninety-three per cent of cancer patients had raised urinary cyclic GMP concentrations compared to the reference range for healthy subjects. For the non-cancerous and benign groups, 33% and 42% respectively had raised concentrations. The urine cyclic AMP concentrations were similar in all groups. Urine cyclic GMP appeared to rise early in the onset of malignant growth. Successful cancer treatment was accompanied by a dramatic fall in the urine cyclic GMP concentrations, whereas if the treatment was unsuccessful the level did not change. It is concluded that urine cyclic GMP may have important applications in the monitoring of cancer treatment.

Full text

PDF
801

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Broadus A. E., Kaminsky N. I., Hardman J. G., Sutherland E. W., Liddle G. W. Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man. J Clin Invest. 1970 Dec;49(12):2222–2236. doi: 10.1172/JCI106441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Criss W. E., Murad F. Urinary excretion of cyclic guanosine 3':5'-monophosphate and cyclic adenosine 3':5'-monophosphate in rats bearing transplantable liver and kidney tumors. Cancer Res. 1976 May;36(5):1714–1716. [PubMed] [Google Scholar]
  3. Curtis-Prior P. B., Gibbons J. R., Chan Y. H. Cyclic nucleotide phosphodiesterase activity of human normal and carcinomatous lung tissue. Lancet. 1976 Dec 4;2(7997):1224–1224. doi: 10.1016/s0140-6736(76)91146-6. [DOI] [PubMed] [Google Scholar]
  4. DeRubertis F. R., Chayoth R., Field J. B. The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon. J Clin Invest. 1976 Mar;57(3):641–649. doi: 10.1172/JCI108320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DeRubertis F. R., Chayoth R., Field J. B. The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon. J Clin Invest. 1976 Mar;57(3):641–649. doi: 10.1172/JCI108320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dusheiko G. M., Levin J., Kew M. C. Cyclic nucleotides in biological fluids in hepatocellular carcinoma. Cancer. 1981 Jan 1;47(1):113–118. doi: 10.1002/1097-0142(19810101)47:1<113::aid-cncr2820470119>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  7. Gennari C., Francini G., Galli M., Lore F. Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy. J Clin Pathol. 1978 Aug;31(8):735–741. doi: 10.1136/jcp.31.8.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goldberg N. D., Haddox M. K., Nicol S. E., Glass D. B., Sanford C. H., Kuehl F. A., Jr, Estensen R. Biologic regulation through opposing influences of cyclic GMP and cyclic AMP: the Yin Yang hypothesis. Adv Cyclic Nucleotide Res. 1975;5:307–330. [PubMed] [Google Scholar]
  9. Guerinot F., Delarue J. C., Contesso G., Bohuon C. Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate levels in human breast cancer tissue. Oncology. 1977;34(6):261–263. doi: 10.1159/000225238. [DOI] [PubMed] [Google Scholar]
  10. Hickie R. A., Thompson W. J., Strada S. J., Couture-Murillo B., Morris H. P., Robison G. A. Comparison of cyclic adenosine 3':5'-monophosphate and cyclic guanosine 3':5'-monophosphate levels, cyclases, and phosphodiesterases in Morris hepatomas and liver. Cancer Res. 1977 Oct;37(10):3599–3606. [PubMed] [Google Scholar]
  11. Hunt N. H., Smith B., Pembrey R. Cyclic nucleotide excretion in human malignancies. Clin Sci (Lond) 1980 Jun;58(6):463–467. doi: 10.1042/cs0580463. [DOI] [PubMed] [Google Scholar]
  12. Latner A. L., Prudhoe K. A simplified competitive protein-binding assay for adenosine 3',5'-monophosphate in plasma. Clin Chim Acta. 1973 Nov 15;48(4):353–357. doi: 10.1016/0009-8981(73)90412-9. [DOI] [PubMed] [Google Scholar]
  13. Sato T., Saito K., Takezawa J., Fujishima T., Iijima T., Kuninaka A., Yoshino H. Urinary excretion of cyclic nucleotides and principal electrolytes in healthy humans of different ages. Clin Chim Acta. 1981 Mar 5;110(2-3):215–225. doi: 10.1016/0009-8981(81)90350-8. [DOI] [PubMed] [Google Scholar]
  14. Shima S., Kawashima Y., Hirai M., Kouyama H. Studies on cyclic nucleotides in cancer. I. Adenylate guanylate cyclase and protein kinases in the prostatic sarcoma tissue. Biochim Biophys Acta. 1976 Sep 24;444(2):571–578. doi: 10.1016/0304-4165(76)90401-3. [DOI] [PubMed] [Google Scholar]
  15. Turner G. A., Ellis R. D., Guthrie D., Latner A. L., Skillen A. W., Ross W. M. Levels of adenosine 3',5' cyclic monophosphate and guanosine 3',5' cyclic monophosphate in single urine specimens collected from a large population of healthy subjects. Ann Clin Biochem. 1982 Mar;19(Pt 2):77–82. doi: 10.1177/000456328201900203. [DOI] [PubMed] [Google Scholar]
  16. Wood P. J., Ross G., Smith C. L. Plasma and urine cyclic nucleotide levels in malignant disease and cirrhosis of the liver. J Clin Pathol. 1979 Oct;32(10):998–1002. doi: 10.1136/jcp.32.10.998. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES